The Racing Medication and Testing Consortium’s (RMTC) Scientific Advisory Committee has performed an analysis of HISA’s proposed Anti-Doping and Medication Control program (ADMC) and, where data permits, developed withdrawal guidance associated with the ADMC Screening Limits and Detections Times of the schedule of RMTC Controlled Therapeutic Substances (CTS).
Among the guidelines issued for non-steroidal anti-inflammatories, the shortest recommended withdrawal time is for Ketoprofen at 72 hours (at 2.2 mg/kg single IV dose). The other two NSAIDs for which guidelines were issued, Flunixin Meglumine (Banamine) and Phenylbutazone (Bute), have withdrawal times of at least 96 hours (IV administration).
The withdrawal guidance is available through this link.
Withdrawal guidelines are for informational purposes only. It is advisable that this information should be used by horsemen in consultation with their attending veterinarian. The withdrawal guidelines do not constitute a guarantee or warranty.
HISA’s expected ADMC implementation date is March 27, 2023.
Also, the Withdrawal Guidance is subject to change. As new research becomes available for each medication, the RMTC may extend or decrease the time listed in the Withdrawal Guidance. Any subsequent change in this information based upon new research will be provided upon review by the Scientific Advisory Committee and approval by the RMTC Board.
The AJC is a staunch supporter of the efforts of the Racing Medication and Testing Consortium. The RMTC is a 501(c) 3 organization comprised of 23 industry stakeholder organizations with a shared commitment to engage in research, education, and advocacy for science-based initiatives that promote the health and safety of the racehorse and the integrity of competition. More information can be found at RMTCnet.com.
